Aprezo（Otezla）30mg, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:
1.Adult patients with active psoriatic arthritis
2.Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
DOSAGE AND ADMINISTRATION
To reduce risk of gastrointestinal symptoms, titrate to recommended dose of 30 mg twice daily according to the following schedule
Day 1: 10 mg in morning
Day 2: 10 mg in morning and 10 mg in evening
Day 3: 10 mg in morning and 20 mg in evening
Day 4: 20 mg in morning and 20 mg in evening
Day 5: 20 mg in morning and 30 mg in evening
Day 6 and thereafter: 30 mg twice daily
Dosage in Severe Renal Impairment:
Recommended dose is 30 mg once daily
For initial dosage titration, titrate using only morning schedule listed in Table 1 and skip afternoon doses
Aprezo’s brand name is Otezla® by Celgene. Aprezo is a generic oncologic prescription medicine from Glenmark, which is the biggest pharmaceutical company in India.
For more Prescribing information，please check the → “FDA Prescribing Information”
80.00 per 30 Tablets
